3 results about "Medication hypertension" patented technology

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

The present invention relates to novel sublingual compositions comprising an anti-fibrotic agent, as well as methods for their preparation. Wherein the composition comprising an anti- fibrotic agent such as pirfenidone or nintedanib and its analogs or pharmaceutically acceptable salts thereof. These novel sublingual compositions are intended for use in the treatment of fibrotic diseases, disorders, or conditions, such as idiopathic pulmonary fibrosis (IPF), and hypertensive diseases, disorders, or conditions such as pulmonary hypertension.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).